Rocket Pharmaceuticals, Inc.(RCKT)

Biotechnology · Cranbury, NJ

$2.48-0.13 (-4.82%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

Compare

EBITDA Margin: N/A

Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA margin is N/A as of Tuesday, October 6, 2026.

EBITDA|Gross Margin|Operating Margin|Profit Margin|All Metrics

RCKT EBITDA Margin Metrics

EBITDA MARGIN

N/A

RCKT Competitors' EBITDA Margin

RCKT

Rocket Pharmaceuticals, Inc.

Current

Market Cap

$271.26M

EBITDA Margin

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VNDA

Vanda Pharmaceuticals Inc.

vs RCKT

Market Cap

$271.51M

EBITDA Margin

-64.44%

TTM Avg

-40.40%

3Y Avg

-20.73%

5Y Avg

-9.01%

SABS

SAB Biotherapeutics, Inc.

vs RCKT

Market Cap

$269.63M

EBITDA Margin

-2882.46%

TTM Avg

-2207.86%

3Y Avg

-1135.55%

5Y Avg

-791.10%

FATE

Fate Therapeutics, Inc.

vs RCKT

Market Cap

$266.92M

EBITDA Margin

-2082.59%

TTM Avg

-1743.06%

3Y Avg

-1015.79%

5Y Avg

-806.48%

SCTX

Scribe Therapeutics Inc.

vs RCKT

Market Cap

$266.68M

EBITDA Margin

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EYPT

EyePoint Pharmaceuticals, Inc.

vs RCKT

Market Cap

$265.78M

EBITDA Margin

-768.62%

TTM Avg

-551.06%

3Y Avg

-374.75%

5Y Avg

-290.29%

IKT

Inhibikase Therapeutics, Inc.

vs RCKT

Market Cap

$262.75M

EBITDA Margin

-7643.91%

TTM Avg

-11162.31%

3Y Avg

-5581.16%

5Y Avg

-3720.77%

TLSI

TriSalus Life Sciences, Inc.

vs RCKT

Market Cap

$261.69M

EBITDA Margin

-58.29%

TTM Avg

-89.32%

3Y Avg

-189.95%

5Y Avg

-208.07%

BBOT

BridgeBio Oncology Therapeutics Inc.

vs RCKT

Market Cap

$280.37M

EBITDA Margin

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TMCI

Treace Medical Concepts, Inc.

vs RCKT

Market Cap

$260.79M

EBITDA Margin

-20.52%

TTM Avg

-21.55%

3Y Avg

-22.69%

5Y Avg

-17.32%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Rocket Pharmaceuticals, Inc. (RCKT)	$271.26M	N/A	N/A	N/A	N/A
Vanda Pharmaceuticals Inc. (VNDA)vs ›	$271.51M	-64.44%	-40.40%	-20.73%	-9.01%
SAB Biotherapeutics, Inc. (SABS)vs ›	$269.63M	-2882.46%	-2207.86%	-1135.55%	-791.10%
Fate Therapeutics, Inc. (FATE)vs ›	$266.92M	-2082.59%	-1743.06%	-1015.79%	-806.48%
Scribe Therapeutics Inc. (SCTX)vs ›	$266.68M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$265.78M	-768.62%	-551.06%	-374.75%	-290.29%
Inhibikase Therapeutics, Inc. (IKT)vs ›	$262.75M	-7643.91%	-11162.31%	-5581.16%	-3720.77%
TriSalus Life Sciences, Inc. (TLSI)vs ›	$261.69M	-58.29%	-89.32%	-189.95%	-208.07%
BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›	$280.37M	N/A	N/A	N/A	N/A
Treace Medical Concepts, Inc. (TMCI)vs ›	$260.79M	-20.52%	-21.55%	-22.69%	-17.32%

Margin Comparison

Gross Margin

0.0%

EBITDA Margin

N/A

Operating Margin

0.0%

Net Margin

0.0%

Formula: EBITDA Margin = (EBITDA / Revenue) × 100

Why EBITDA Margin matters:

Removes effects of depreciation policies (D&A)
Capital structure neutral (ignores interest)
Tax neutral (ignores tax differences)
Good proxy for operating cash generation

EBITDA Margin Formula & Definition

EBITDA Margin = EBITDA / Revenue

EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

Cranbury, NJ

202 employees

rocketpharma.com

Healthcare / Biotechnology